Explore the Global Leukocyte Adhesion Deficiency Management Market — Key Trends, Regional Growth, Top Players, and 10-Year Forecast from 2026 to 2036

Future Market Insights

Leukocyte Adhesion Deficiency Management Market

Key Insight

Hematopoietic stem cell transplantation will lead leukocyte adhesion deficiency management sales through 2036 with 62.0% of the treatment segment in 2026. The market was valued at USD 9.18 billion in 2025 and grows from USD 9.8 billion in 2026 to USD 18.7 billion by 2036, creating an incremental opportunity of USD 8.94 billion.

April 21, 2026

Anurag Sharma

299 Pages

Cite this Report

Leukocyte Adhesion Deficiency Management Market

https://www.futuremarketinsights.com/reports/leukocyte-adhesion-deficiency-management-market

License

Buy Now

Summary ToC Infographics Companies

Key Players

Avrobio Inc
Be The Match BioTherapies
Bluebird Bio
CSL Behring
Gilead Sciences
Lonza
Magenta Therapeutics
Novartis Gene Therapies
Orchard Therapeutics
Rocket Pharmaceuticals

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Leukocyte Adhesion Deficiency Management Market

Key Players

Similar Industry Reports